Manufacturing capabilities

Patients count on us to deliver quality medicines where and when they are needed. Here is how we work to meet that demand.

Strategic Principles

Pursue top quality science, internally and externally, balanced with medical need and commercial potential.

 

Product / Technology In

NMEs with clinical validated targets/MOA and solid IP rights, including Fast-followers and Biobetters Strengthening Genocore’s NME pipeline by leveraging mature external drug discovery technology platforms.

Product Out

For Genocore products in our pipeline (both Biosimilars and NMEs), after we complete process development and preclinical study, we are actively seeking regional or global partners to undertake clinical development and commercialization in overseas pharmemerging markets, and in more developed markets.

For both Product In and Product Out, collaboration models can include: product licensing, co-development, JV and risk-sharing strategic partnerships with NMCs.

Please contact our business development team if you have interest in any of these opportunities, or other creative new ideas/suggestions regarding collaboration. We look forward to building mutually beneficial partnerships with you!

Genocore Biotech’s commitment to improving the lives of patients guides every aspect of our manufacturing operations. We take our responsibility of making and delivering quality medicine very seriously. In recent years we have extended our expertise into the production of small molecule therapies and have fully integrated an oral solid dose facility into our manufacturing infrastructure.

We attribute our success to excellence in several key areas. Our process development team continually advances our understanding of the biology and the process technology that are both critical to improving our capabilities and output. Our advanced engineering teams ensure that our manufacturing plants are state of the art with cutting-edge technologies to meet demand for our existing therapies, clinical trials and opportunities in biosimilars. Our world-class manufacturing teams are the key to efficient and reliable operation of these assets. Thorough business continuity planning provides redundancy on a global level to ensure product availability. In addition, these teams create systems that minimize our impact on the environment by limiting waste and using resources efficiently.

Our quality team manages compliance and supervises consistent and dependable production of our therapies, while our supply chain group makes sure that we are able to get our therapies to patients, when and where they need them.

In the coming years we expect to substantially increase our production capabilities by focusing on innovation that allows us to scale in advance of new pipeline products. Today we can rapidly increase production of small molecules and biologics, providing flexibility and protection to our supply chain.

 

Our Research

Patients are at the forefront of our R&D strategy. We understand that patients suffering from severe, life-threatening rare diseases often have no effective treatment options and little hope. Our R&D teams focus exclusively on these underserved patient populations, and work closely with the medical community to understand the pathophysiology, natural history and clinical consequences of these devastating diseases, so that we can identify and investigate potential breakthrough therapies. Our R&D capabilities include translational research, bench sciences, chemistry, biology and biochemistry, through to clinical operations, clinical development and regulatory affairs.

Our research programs span several therapeutic areas including hematology, nephrology, transplant, neurology, metabolic disorders and inflammatory disorders. We have programs underway with highly innovative therapeutic candidates, including eculizumab, that have the potential to become first-in-class therapies for patients with severe and life-threatening disorders.